PDS Biotechnology Q2 net loss widens slightly as operating costs fall
PDSB•Analyst coverage
The current average analyst rating on the shares is buy, with 3 strong buy or buy recommendations, no hold ratings, and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology and medical research peer group is buy. Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 1,759.5% above its August 12 closing price of $0.24.
Strategic refocus and outlook
PDS Biotechnology said it will prioritize PDS0301 as its lead program and discontinue internal investment in PDS0101.
The company said it will seek partnerships for continued development of PDS0101.
Higher net interest expense also weighed on results, due to a non-cash charge for loss on retirement of debt.
Q2 loss widens slightly as expenses decline
PDS Biotechnology said its second-quarter net loss widened slightly year over year, even as operating expenses fell on lower clinical trial, manufacturing and personnel costs.
The company reported a Q2 loss per share of $0.18, missing the consensus estimate of from two analysts. Net loss was .
Related News
Opko Health issues additional $125 million senior secured notes backed by mazdutide royalties
SuperCom Q2 FY26 non-GAAP net income rises 32% to $2.9 million; revenue increases 13.3% to $8.1 million
